import streamlit as st
import google.generativeai as genai

# --- ğŸ¥ å©¦ç™Œè‡¨åºŠå°èˆªèˆ‡å¯¦è­‰åœ–æ›¸é¤¨ (2026 æ——è‰¦æœ€çµ‚æ¥µé‡æ•´åˆç‰ˆ) ---
st.set_page_config(page_title="å©¦ç™Œè‡¨åºŠè©¦é©—å°èˆªç³»çµ±", layout="wide")

# åˆå§‹åŒ– session_state ç”¨æ–¼è¯å‹•èˆ‡æŒä¹…åŒ–
if 'selected_trial' not in st.session_state:
    st.session_state.selected_trial = "ğŸ“š RUBY (ENGOT-EN6)"

st.markdown("""
    <style>
    @import url('https://fonts.googleapis.com/css2?family=Noto+Sans+TC:wght@400;700;900&family=Roboto:wght@400;700;900&display=swap');
    
    /* === UI é«˜å°æ¯”åº¦èˆ‡è¦–è¦ºæ•‘æ´ === */
    html, body, [class*="css"] {
        font-family: 'Noto Sans TC', 'Roboto', sans-serif;
        background-color: #F4F7F9; color: #1A1A1A;
        font-size: 19px !important; line-height: 1.1;
    }

    .main-title {
        font-size: 32px !important; font-weight: 900; color: #004D40;
        padding: 5px 0; border-bottom: 3px solid #4DB6AC; margin-bottom: 5px;
    }

    /* éšæ®µæ–¹å¡Šæ·±è‰²æ¼¸å±¤èƒŒæ™¯ */
    .big-stage-card {
        border-radius: 12px; padding: 0px; box-shadow: 0 4px 20px rgba(0,0,0,0.15);
        border: 2.5px solid transparent; background: white; margin-bottom: 6px; overflow: hidden; height: auto !important;
    }
    .big-stage-header {
        font-size: 19px !important; font-weight: 900; color: white !important;
        padding: 12px; text-align: center; text-shadow: 1px 1px 3px rgba(0,0,0,0.4);
    }

    /* é…è‰²å¼·åŒ– */
    .card-p-tx { border-color: #1B5E20; }
    .header-p-tx { background: linear-gradient(135deg, #2E7D32, #1B5E20); } /* Primary Tx */
    .card-p-mt { border-color: #0D47A1; }
    .header-p-mt { background: linear-gradient(135deg, #1565C0, #0D47A1); } /* 1L Maint */
    .card-r-tx { border-color: #E65100; }
    .header-r-tx { background: linear-gradient(135deg, #EF6C00, #BF360C); } /* Recurr Tx */
    .card-r-mt { border-color: #4A148C; }
    .header-r-mt { background: linear-gradient(135deg, #6A1B9A, #4A148C); } /* PR-Maint */

    .sub-block {
        margin: 4px 6px; padding: 6px; border-radius: 8px; 
        background: #F8F9FA; border-left: 6px solid #455A64;
    }
    .sub-block-title {
        font-size: 15px; font-weight: 900; color: #263238;
        margin-bottom: 2px; border-bottom: 1.2px solid #CFD8DC; padding-bottom: 2px;
    }

    .stPopover button { 
        font-weight: 900 !important; font-size: 12px !important; 
        border-radius: 5px !important; margin-top: 2px !important;
        padding: 2px 8px !important; width: 100% !important; 
        text-align: left !important; color: #1A1A1A !important; 
        border: 1.2px solid rgba(0,0,0,0.18) !important;
        box-shadow: 0 1.5px 4px rgba(0,0,0,0.12) !important;
    }
    
    .stPopover button[aria-label*="ğŸ“š"] { background: #ECEFF1 !important; border-left: 6px solid #455A64 !important; }
    .stPopover button[aria-label*="ğŸ“"] { background: #E1F5FE !important; border-left: 6px solid #0288D1 !important; } 

    .detail-section { background: white; border-radius: 20px; padding: 30px; border: 1.5px solid #CFD8DC; box-shadow: 0 10px 40px rgba(0,0,0,0.08); }
    .hr-big-val { font-family: 'Roboto', sans-serif; font-size: 34px !important; font-weight: 900; color: #D84315; }
    .regimen-box { background: #F1F8E9; border-left: 5px solid #689F38; padding: 10px; margin: 5px 0; border-radius: 5px; font-size: 14px; }
    </style>
    """, unsafe_allow_html=True)

# --- 1. æŒ‡å¼•æ•¸æ“šåº«ï¼šç²¾ç¢ºåˆ†å‹èˆ‡è·¯å¾‘æ•‘æ´ (EC/OC/CC) ---
guidelines_nested = {
    "Endometrial": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "dMMR / MSI-H / MMRd", "content": "ä¸€ç·šæ¨™ç«¿ï¼šChemo + PD-1 (RUBY/GY018/AtTEnd)ã€‚"},
            {"title": "pMMR / NSMP / MSS", "content": "ER/Grade åˆ†æµã€‚ä¸€ç·šåŒ–ç™‚åŠ ç¶­æŒ (DUO-E)ã€‚äºŒç·šæ¨™é¶å…ç–« (KN775)ã€‚"},
            {"title": "POLE mutation (è¶…çªè®Š)", "content": "é å¾Œæ¥µä½³ï¼Œæ—©æœŸå¯é™éšæ²»ç™‚ã€‚æ™šæœŸå¯¦è­‰æŒçºŒç´¯ç©ä¸­ã€‚"},
            {"title": "p53 mutation (é«˜æ‹·è²)", "content": "é å¾Œæœ€å·®ã€‚å»ºè­°åŒ–æ”¾ç™‚ç©æ¥µä»‹å…¥ã€‚Serous å‹éœ€æª¢æ¸¬ HER2ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "Maintenance", "content": "ä¸€ç·š IO å¾Œå»¶çºŒç¶­æŒè‡³ PD (MK2870-033/DUO-E/RUBY)ã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [{"title": "Recurrent EC", "content": "æ¨™é¶+å…ç–« (KN775) æˆ–å–®è—¥ IO (GARNET)ã€‚æ•‘æ´ ADC (SG)ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Tx", "content": "å¾©ç™¼ç·©è§£å¾Œç¶­æŒæœ‰æ•ˆæ–¹æ¡ˆç›´è‡³é€²å±•ã€‚"}]}
    ],
    "Ovarian": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "HGSC / Endometrioid", "content": "PDS/IDS + Carbo/Pacli Â± Bevã€‚è€ƒæ…® IDS åŠ  HIPEC (van Driel)ã€‚"},
            {"title": "Mucinous (MOC) é‘‘å®š", "content": "åˆ¤å®šï¼šCK7+/SATB2-ã€‚Expansile (IAå¯ä¿å®ˆ) vs Infiltrativeã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [
            {"title": "BRCA mutation", "content": "Olaparib ç¶­æŒ 2å¹´ (SOLO-1)ã€‚"}, 
            {"title": "HRD positive / BRCA wt", "content": "PAOLA-1 (Ola+Bev) æˆ– PRIMA (Nira) æˆ– DUO-Oã€‚"},
            {"title": "HRD negative (pHRD)", "content": "Niraparib ç¶­æŒ (PRIMA ITT) æˆ– Bevacizumabã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [
            {"title": "PSOC (Sensitive)", "content": "PFI > 6mã€‚è©•ä¼°äºŒæ¬¡æ‰‹è¡“ (DESKTOP III) æˆ–å«é‰‘è¤‡æ–¹ã€‚"},
            {"title": "PROC (Resistant)", "content": "PFI < 6mã€‚å–®è—¥åŒ–ç™‚ Â± Bev æˆ–æ¨™é¶ ADC (MIRASOL/FRAmework)ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "PARPi Maint", "content": "æ•‘æ´ç·©è§£å¾ŒçºŒç”¨ PARPi (NOVA/ARIEL3/SOLO2)ã€‚"}]}
    ],
    "Cervical": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "Locally Advanced (CCRT)", "content": "åŒæ­¥åŒ–æ”¾ç™‚ Â± åŒæ­¥ IO (A18) æˆ– èª˜å°åŒ–ç™‚ (INTERLACE)ã€‚"},
            {"title": "Early Stage (Surgery)", "content": "æ ¹æ²»è¡“ (LACC) æˆ–å–®ç´”åˆ‡é™¤ (SHAPE)ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "Maintenance", "content": "1L æ–¹æ¡ˆå¾Œæ¥çºŒç¶­æŒ (KEYNOTE-826)ã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [
            {"title": "Recurr / Metastatic", "content": "ä¸€ç·š KN826/BEATccã€‚äºŒç·š ADC (innovaTV 301) æˆ– IOã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Therapy", "content": "ç¶­æŒæœ‰æ•ˆæ•‘æ´æ–¹æ¡ˆç›´è‡³ PDã€‚"}]}
    ]
}

# --- 2. å¯¦è­‰è³‡æ–™åº« (33 é …è©¦é©—å…¨é‡æ•¸æ“šæ¥µç·»åŒ–) ---
all_trials_db = [
    # ==========================
    # === Endometrial (å·²ç™¼è¡¨) ===
    # ==========================
    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["dMMR / MSI-H / MMRd"], "name": "ğŸ“š RUBY (ENGOT-EN6/GOG-3031)", "pharma": "GSK", "drug": "Dostarlimab + CP", 
     "results_short": "dMMR æ­»äº¡é¢¨éšªé™ä½ 68% (HR 0.32)",
     "rationale": "PD-1 é˜»æ–· (PD-1 blockade) èˆ‡å«é‰‘åŒ–ç™‚ (Platinum-based Chemo) å…·æœ‰å”åŒå…ç–«åŸæ€§ç´°èƒæ­»äº¡ (ICD) æ•ˆæ‡‰ã€‚",
     "regimen": "Arm A: Dostarlimab 500mg Q3W + CP x6 é€±æœŸ -> Maint: Dostarlimab 1000mg Q6W (3å¹´)ã€‚ Arm B: Placebo + CP x6 é€±æœŸã€‚",
     "inclusion": ["æ–°è¨ºæ–· FIGO Stage III-IV æˆ–é¦–æ¬¡å¾©ç™¼ä¹‹å­å®®å…§è†œç™Œ (EC)ã€‚", "ECOG 0-1ã€‚", "å« Carcinosarcoma / Clear cell ç­‰çµ„ç¹”å‹æ…‹ã€‚"],
     "exclusion": ["å…ˆå‰æ¥å—éç³»çµ±æ€§åŒ–ç™‚ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…ã€‚"],
     "outcomes": "dMMR 24m PFS: 61.4% vs 15.7% (HR 0.28); ITT OS HR 0.64 (95% CI 0.46-0.87, P=0.0021)."},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["dMMR / MSI-H / MMRd", "pMMR / NSMP / MSS"], "name": "ğŸ“š NRG-GY018 (KEYNOTE-868)", "pharma": "MSD", "drug": "Pembrolizumab + CP", 
     "results_short": "dMMR PFS HR 0.30; pMMR HR 0.54",
     "rationale": "åˆ©ç”¨å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ (ICI) é‡å¡‘è…«ç˜¤å¾®ç’°å¢ƒï¼Œæå‡ä¸€ç·šæ™šæœŸæ‚£è€…ä¸è«– MMR ç‹€æ…‹ä¹‹å­˜æ´»ç‡ã€‚",
     "regimen": "Arm A: Pembrolizumab 200mg Q3W + CP x6 -> Maint: Pembro 400mg Q6W (2å¹´)ã€‚ Arm B: Placebo + CPã€‚",
     "inclusion": ["Stage III/IV æˆ–å¾©ç™¼ ECã€‚", "æ¸¬å¾— MMR ç‹€æ…‹ã€‚"],
     "outcomes": "dMMR PFS HR 0.30 (95% CI 0.19-0.48); pMMR PFS HR 0.54 (95% CI 0.41-0.71)."},

    {"cancer": "Endometrial", "pos": "P-MT", "sub_pos": ["pMMR / NSMP / MSS"], "name": "ğŸ“š DUO-E (ENGOT-EN9)", "pharma": "AZ", "drug": "Durvalumab + CP â†’ç¶­æŒ Â± Olaparib", 
     "results_short": "ä¸‰è—¥çµ„ pMMR PFS HR 0.57 (vs CP)",
     "rationale": "æ¢ç´¢ PARP æŠ‘åˆ¶åŠ‘ (PARPi) åœ¨ pMMR æ—ç¾¤å…ç–«ç¶­æŒéšæ®µçš„å¢æ•èˆ‡å”åŒä½œç”¨ã€‚",
     "regimen": "Arm 1: CP alone; Arm 2: CP+Durva -> Durva Maint; Arm 3: CP+Durva -> Durva+Ola Maint (300mg bid)ã€‚",
     "outcomes": "pMMR Arm 3 vs Arm 1: PFS HR 0.57 (95% CI 0.42-0.79); dMMR Arm 2 vs 1: HR 0.42."},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["dMMR / MSI-H / MMRd"], "name": "ğŸ“š AtTEnd (ENGOT-EN7)", "pharma": "Roche", "drug": "Atezolizumab + CP", 
     "results_short": "dMMR PFS HR 0.36; ITT OS HR 0.82",
     "outcomes": "dMMR PFS: æœªé”åˆ° vs 6.9m (HR 0.36, 95% CI 0.23-0.57); å…¨äººç¾¤ mOS HR 0.82 (P=0.048)."},

    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š KEYNOTE-775 (Study 309)", "pharma": "MSD/Eisai", "drug": "Lenvatinib + Pembrolizumab", 
     "results_short": "pMMR/MSS äºŒç·šæ¨™æº–ï¼šOS 17.4m vs 12.0m",
     "rationale": "çµåˆ VEGF-TKI é‡å¡‘è¡€ç®¡ä¸¦æ¸›è¼•å…ç–«æŠ‘åˆ¶ï¼Œå…‹æœ MSS è…«ç˜¤å°å–®è—¥å…ç–«ä¹‹å†·å¾®ç’°å¢ƒã€‚",
     "regimen": "Lenvatinib 20mg QD + Pembrolizumab 200mg Q3W ç›´è‡³ç–¾ç—…é€²å±•ã€‚",
     "inclusion": ["å…ˆå‰å«é‰‘åŒ–ç™‚å¾Œé€²å±•ä¹‹æ™šæœŸ ECã€‚", "ECOG 0-1ã€‚", "ä¸é™ MMR ç‹€æ…‹ã€‚"],
     "outcomes": "pMMR OS: 17.4m vs 12.0m (HR 0.68, 95% CI 0.56-0.84, P<0.001)."},

    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š GARNET", "pharma": "GSK", "drug": "Dostarlimab (Single-agent)", 
     "results_short": "dMMR ORR 45.5%; DOR æŒä¹…",
     "outcomes": "dMMR/MSI-H ORR 45.5%; 12å€‹æœˆåæ‡‰æŒçºŒç‡ 83.7%ã€‚"},

    # ==========================
    # === Cervical (å·²ç™¼è¡¨) ===
    # ==========================
    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Locally Advanced (CCRT)"], "name": "ğŸ“š KEYNOTE-A18 (ENGOT-cx11)", "pharma": "MSD", "drug": "Pembrolizumab + CCRT", 
     "results_short": "LACC æ¨™æº–ï¼š36m OS 82.6% (HR 0.67)",
     "rationale": "å°‡å…ç–«æ­£å¼ä½µå…¥é«˜é¢¨éšªå±€éƒ¨æ™šæœŸä¹‹æ ¹æ²»æ€§åŒæ­¥åŒ–æ”¾ç™‚ã€‚",
     "regimen": "Cisplatin + RT åŒæ­¥ Pembro 200mg Q3W x5 é€±æœŸ -> ç¶­æŒ Pembro 400mg Q6W x15 é€±æœŸã€‚",
     "inclusion": ["æ–°è¨ºæ–· FIGO 2014 Stage IB2-IIB LN+ æˆ– Stage III-IVA å±€éƒ¨æ™šæœŸã€‚"],
     "outcomes": "24m PFS: 68% vs 57% (HR 0.70); 36m OS: 82.6% vs 74.8% (HR 0.67)."},

    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Locally Advanced (CCRT)"], "name": "ğŸ“š INTERLACE", "pharma": "UCL", "drug": "Induction Carbo/Pacli x6 -> CCRT", 
     "results_short": "5å¹´ OS 80% (vs 72%, HR 0.60)",
     "rationale": "åˆ©ç”¨èª˜å°åŒ–ç™‚ (Induction Chemo) è§£æ±ºæ ¹æ²»æ€§æ”¾ç™‚å‰çš„å¾®å°è½‰ç§»ç—…ç¶ã€‚",
     "regimen": "èª˜å°æœŸ: Paclitaxel 80mg/m2 + Carboplatin AUC2 æ¯é€±ä¸€æ¬¡ x6 é€±æœŸ -> åŒæ­¥æ”¾åŒ–ç™‚ã€‚",
     "outcomes": "5yr OS: 80% vs 72% (HR 0.60, 95% CI 0.44-0.82); 5yr PFS: 73% vs 64% (HR 0.65)."},

    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Locally Advanced (CCRT)"], "name": "ğŸ“š CALLA", "pharma": "AZ", "drug": "Durvalumab + CCRT", 
     "results_short": "æ•´é«”é™°æ€§çµæœ (HR 0.84)",
     "outcomes": "PFS HR 0.84 (95% CI 0.65-1.08, P=0.174)."},

    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurr / Metastatic"], "name": "ğŸ“š KEYNOTE-826", "pharma": "MSD", "drug": "Pembrolizumab + Chemo Â± Bev", 
     "results_short": "R/M ä¸€ç·šæ¨™æº–ï¼šOS HR 0.63",
     "rationale": "ä¸€ç·šè½‰ç§»æ€§å­å®®é ¸ç™Œå…ç–«åŠ åŒ–ç™‚çš„é»ƒé‡‘æ¨™æº–ã€‚",
     "outcomes": "CPSâ‰¥1 mOS: 28.6m vs 16.5m (HR 0.60, 95% CI 0.49-0.74); å…¨äººç¾¤ OS HR 0.63."},

    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurr / Metastatic"], "name": "ğŸ“š BEATcc (ENGOT-Cx10)", "pharma": "Roche", "drug": "Atezolizumab + Chemo + Bev", 
     "results_short": "PFS 13.7m vs 10.4m (HR 0.62)",
     "outcomes": "mPFS: 13.7m vs 10.4m (HR 0.62); mOS: 32.1m vs 22.8m (HR 0.68)."},

    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurr / Metastatic"], "name": "ğŸ“š EMPOWER-Cervical 1", "pharma": "Regeneron", "drug": "Cemiplimab vs Chemo", 
     "results_short": "äºŒç·šå¾Œå–®è—¥å…ç–« OS åŸºçŸ³ï¼šOS HR 0.69",
     "outcomes": "mOS ITT: 12.0m vs 8.5m (HR 0.69, 95% CI 0.56-0.84)."},

    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurr / Metastatic"], "name": "ğŸ“š innovaTV 301 (ENGOT-cx12)", "pharma": "Genmab", "drug": "Tisotumab Vedotin (ADC)", 
     "results_short": "é¦–å€‹ OS ç²ç›Š ADCï¼šOS HR 0.70; ORR 17.8%",
     "rationale": "æ¨™é¶çµ„ç¹”å› å­ (TF) ADCï¼Œç²¾æº–è¼¸é€ MMAE æ®ºå‚·å¾Œç·šåŒ–ç™‚è€è—¥ç™Œç´°èƒã€‚",
     "outcomes": "mOS: 11.5m vs 9.5m (HR 0.70, 95% CI 0.54-0.89); ORR 17.8% vs 5.2%."},

    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Early Stage (Surgery)"], "name": "ğŸ“š SHAPE trial", "pharma": "CCTG", "drug": "Simple Hysterectomy", 
     "results_short": "ä½é¢¨éšªé™éšï¼š3yr ç›†è…”å¾©ç™¼ 2.5% vs 2.2%",
     "outcomes": "3yr Pelvic Recurrence: 2.5% (SH) vs 2.2% (RH) (HR 1.12, 90% CI 0.61-2.03)."},

    # ==========================
    # === Ovarian (å·²ç™¼è¡¨) ===
    # ==========================
    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["BRCA mutation"], "name": "ğŸ“š SOLO-1", "pharma": "AZ", "drug": "Olaparib Maint", 
     "results_short": "BRCAm æ²»ç™’æ½›åŠ›ï¼š7yrå­˜æ´»ç‡ 67% (HR 0.33)",
     "outcomes": "mPFS: 56.0m vs 13.8m (HR 0.30); 7yr Survival 67.0% vs 46.5%."},

    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["HRD positive / BRCA wt", "HRD negative (pHRD)"], "name": "ğŸ“š PRIMA (ENGOT-OV26)", "pharma": "GSK", "drug": "Niraparib Maint", 
     "results_short": "å…¨äººç¾¤ä¸€ç·šç¶­æŒï¼šHRD+ PFS HR 0.43",
     "rationale": "ä¸é™ BRCA çªè®Šï¼Œæ“´å¤§ PARPi åœ¨ä¸€ç·šå«é‰‘åŒ–ç™‚åæ‡‰å¾Œçš„ç²ç›Šç¾¤çœ¾ã€‚",
     "outcomes": "HRD+ PFS HR 0.43 (95% CI 0.31-0.59); ITT HR 0.62."},

    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["HRD positive / BRCA wt"], "name": "ğŸ“š PAOLA-1 (ENGOT-ov25)", "pharma": "AZ", "drug": "Olaparib + Bevacizumab", 
     "results_short": "HRD+ é»ƒé‡‘çµ„åˆï¼š5yr OS 75.2% (HR 0.62)",
     "rationale": "çµåˆ PARPi èˆ‡ anti-VEGF ç¶­æŒè·¯å¾‘ï¼Œé‡å¡‘ DNA ä¿®å¾©æŠ‘åˆ¶èˆ‡å¾®è¡€ç®¡å¾®ç’°å¢ƒã€‚",
     "outcomes": "HRD+ 5yr OS: 75.2% vs 58.3% (HR 0.62, 95% CI 0.45-0.85)."},

    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["BRCA mutation", "HRD positive / BRCA wt"], "name": "ğŸ“š ATHENAâ€“MONO", "pharma": "Clovis", "drug": "Rucaparib Maint", 
     "results_short": "ITT PFS 28.7m (HR 0.52)",
     "outcomes": "HRD+ PFS: 28.7m vs 11.3m (HR 0.47); ITT HR 0.52."},

    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["PARPi Maint"], "name": "ğŸ“š NOVA", "pharma": "GSK", "drug": "Niraparib å¾©ç™¼ç¶­æŒ", 
     "results_short": "gBRCA HR 0.27; non-gBRCA HR 0.45",
     "outcomes": "gBRCA PFS: 21.0m vs 5.5m (HR 0.27); non-gBRCA HR 0.45."},

    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["PARPi Maint"], "name": "ğŸ“š ARIEL3", "pharma": "Clovis", "drug": "Rucaparib å¾©ç™¼ç¶­æŒ", 
     "results_short": "BRCAm PFS HR 0.23; HRD+ HR 0.32",
     "outcomes": "BRCAm mPFS 16.6m vs 5.4m (HR 0.23)."},

    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["PARPi Maint"], "name": "ğŸ“š SOLO2", "pharma": "AZ", "drug": "Olaparib å¾©ç™¼ç¶­æŒ", 
     "results_short": "BRCAm å¾©ç™¼ OSï¼šmOS 51.7m (HR 0.74)",
     "outcomes": "mOS: 51.7m vs 38.8m (HR 0.74, 95% CI 0.54-1.00)."},

    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["HRD positive / BRCA wt"], "name": "ğŸ“š DUO-O", "pharma": "AZ", "drug": "Durva+Ola+Bev ç¶­æŒ", 
     "results_short": "ä¸‰è—¥ç¶­æŒæ½›åŠ›ï¼šHRD+ PFS HR 0.49",
     "outcomes": "HRD+ PFS HR 0.49 (95% CI 0.34-0.69); non-HRD HR 0.68."},

    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["PROC (Resistant)"], "name": "ğŸ“š MIRASOL", "pharma": "ImmunoGen", "drug": "Mirvetuximab", 
     "results_short": "PROC OS çªç ´ï¼šOS HR 0.67; ORR 42.3%",
     "rationale": "é¦–å€‹åœ¨é‰‘é¡æŠ—è—¥æ€§æ‚£è€…è­‰æ˜å…·å‚™å­˜æ´»ç²ç›Š (Overall Survival) ä¹‹ ADCã€‚",
     "regimen": "Mirvetuximab 6.0 mg/kg (Adjusted Ideal Body Weight) IV Q3Wã€‚",
     "outcomes": "mOS: 16.4m vs 12.7m (HR 0.67); mPFS 5.6m vs 4.0m (HR 0.65)."},

    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["HGSC / Endometrioid"], "name": "ğŸ“š van Driel HIPEC (van Driel trial)", "pharma": "NEJM 2018", "drug": "Surgery + HIPEC", 
     "results_short": "IDS åŠ æº«ï¼šmOS å»¶é•· 12 å€‹æœˆ (HR 0.67)",
     "rationale": "è¡“ä¸­åŠ æº«è…¹è…”åŒ–ç™‚ (HIPEC) å¼·åŒ–å°æ®˜ç•™å¾®å°ç—…ç¶çš„ç©¿é€èˆ‡æ®ºå‚·åŠ›ã€‚",
     "regimen": "é–“æ­‡æ¸›ç©æ‰‹è¡“ (IDS) æ™‚åŒæ­¥åŠ æº«çŒæ³¨ Cisplatin (100 mg/m2) 90 åˆ†é˜ã€‚",
     "outcomes": "mOS: 45.7m vs 33.9m (HR 0.67, 95% CI 0.48-0.94); mPFS HR 0.66."},

    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["PSOC (Sensitive)"], "name": "ğŸ“š DESKTOP III", "pharma": "NEJM 2021", "drug": "Secondary Surgery", 
     "results_short": "äºŒæ¬¡æ‰‹è¡“åƒ¹å€¼ï¼šR0 åˆ‡é™¤ mOS 53.7m",
     "rationale": "è­‰æ˜åš´é¸æ‚£è€… (AGO Score+) äºŒæ¬¡æ‰‹è¡“èƒ½è½‰åŒ–ç‚ºé¡¯è‘— OS ç²ç›Šã€‚",
     "regimen": "äºŒæ¬¡æ‰‹è¡“ (Secondary Cytoreduction) æ¥çºŒé‰‘é¡è¤‡æ–¹åŒ–ç™‚ã€‚",
     "inclusion": ["é¦–æ¬¡é‰‘é¡æ•æ„Ÿå¾©ç™¼ (PFI > 6m)ã€‚", "AGO Score é™½æ€§ (ECOG 0/å¤§é‡è…¹æ°´é™¤å¤–/R0æ½›åŠ›)ã€‚"],
     "outcomes": "ITT mOS: 53.7m vs 46.0m (HR 0.75); R0 å®Œå…¨åˆ‡é™¤è€… mOS é” 61.9m."},

    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["HGSC / Endometrioid"], "name": "ğŸ“š LION", "pharma": "NEJM 2019", "drug": "No Lymphadenectomy", 
     "results_short": "è‡¨åºŠ LN é™°æ€§å…æ¸…æƒï¼šOS ç„¡å·®ç•° (HR 1.06)",
     "outcomes": "mOS: 65.5m vs 69.2m (HR 1.06, P=0.65)ã€‚ä¸å»ºè­°è‡¨åºŠ LN(-) è€…ä¾‹è¡Œæ¸…æƒã€‚"},

    # ==========================
    # === Ongoing Trials (æ‹›å‹Ÿä¸­) ===
    # ==========================
    {"cancer": "Ovarian", "name": "ğŸ“ FRAmework-01", "pharma": "Eli Lilly", "drug": "LY4170156 + Bevacizumab", "pos": "R-TX", "sub_pos": ["PROC (Resistant)", "PSOC (Sensitive)"], "type": "Ongoing",
     "pop_summary": "FRÎ± ADC ä½µç”¨ VEGF æŠ‘åˆ¶åŠ‘ï¼šè·¨çµ„æå‡æ»²é€èˆ‡æ®ºå‚·åŠ›ã€‚",
     "rationale": "é€é LY4170156 (FRÎ± ADC) ç²¾æº–æ¨™é¶èˆ‡ Bevacizumab è¡€ç®¡é‡å¡‘ä½œç”¨ç”¢ç”Ÿå”åŒæ•ˆæœã€‚",
     "regimen": "Arm A (PROC): LY 3.0mg/kg + Bev 15mg/kg Q3W; Arm B (PSOC): LY 3.0mg/kg + Bev 15mg/kg Q3W; Arm C: é†«å¸«é¸æ“‡åŒ–ç™‚ã€‚",
     "inclusion": ["ç¶“ä¸­å¤®æª¢æ¸¬ç¢ºèª FRÎ± è¡¨é”é™½æ€§ã€‚", "æœ€å¾Œé‰‘é¡å¾Œé€²å±•ä¹‹ PROC æˆ– PSOC (PFI 6-12m)ã€‚"],
     "exclusion": ["æ›¾ç”¨éé‡å° FRÎ± ä¹‹ ADCã€‚", "æ´»å‹•æ€§é–“è³ªæ€§è‚ºç—… (ILD)ã€‚"]},

    {"cancer": "Ovarian", "name": "ğŸ“ REJOICE-Ovarian01", "pharma": "Daiichi Sankyo", "drug": "R-DXd", "pos": "R-TX", "sub_pos": ["PROC (Resistant)"], "type": "Ongoing",
     "rationale": "æ¨™é¶ CDH6 ADCï¼Œå…·æ¥µé«˜ DAR (8) èˆ‡å¼·æ•ˆæ—è§€è€…æ•ˆæ‡‰æŒ‘æˆ°ç•°è³ªæ€§ PROCã€‚",
     "regimen": "Raludotatug deruxtecan 5.6mg/kg IV Q3W ç›´è‡³é€²å±•ã€‚",
     "inclusion": ["çµ„ç¹”å­¸ HG Serous æˆ– Endometrioid PROCã€‚", "æä¾›åˆ‡ç‰‡åˆ¤å®š CDH6 åˆ†å±¤ã€‚"]},

    {"cancer": "Endometrial", "name": "ğŸ“ MK2870-033", "pharma": "MSD", "drug": "Sac-TMT + Pembrolizumab", "pos": "P-MT", "sub_pos": ["Maintenance Therapy"], "type": "Ongoing",
     "rationale": "æ¨™é¶ Trop-2 ADC å”åŒ PD-1ã€‚æå‡ Pembro åœ¨ pMMR æˆ– NSMP æ—ç¾¤çš„æ‡‰ç­”æ·±åº¦ã€‚",
     "regimen": "Pembrolizumab 400mg Q6W + Sac-TMT 5mg/kg Q6Wã€‚",
     "inclusion": ["pMMR å­å®®å…§è†œç™Œ (ä¸­å¿ƒæª¢æ¸¬)ã€‚", "FIGO III/IV ä¸€ç·šå«é‰‘+Pembroå¾Œé” CR/PRã€‚"]},

    {"cancer": "Endometrial", "name": "ğŸ“ GU-US-682-6769", "pharma": "Gilead", "drug": "SG (Trodelvy)", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "type": "Ongoing",
     "rationale": "é‡å° Trop-2 ADC åˆ©ç”¨ SN-38 è¼‰è·æ®ºå‚·å°æŠ—é‰‘é¡èˆ‡å…ç–«å¤±æ•—æ•‘æ´ã€‚",
     "regimen": "Sacituzumab govitecan 10mg/kg (Day 1, Day 8) Q21Dã€‚",
     "inclusion": ["å¾©ç™¼æ€§ EC (ä¸å«è‚‰ç˜¤)ã€‚", "é‰‘é¡èˆ‡ PD-1 å¤±æ•—å¾Œé€²å±•ã€‚"]},

    {"cancer": "Ovarian", "name": "ğŸ“ DOVE", "pharma": "GSK", "drug": "Dostarlimab + Bevacizumab", "pos": "R-TX", "sub_pos": ["PROC (Resistant)"], "type": "Ongoing",
     "rationale": "é‡å° OCCC é€æ˜ç´°èƒç™Œåˆ©ç”¨é›™é‡é˜»æ–·æ”¹å–„å…¶ç‰¹æœ‰å…ç–«æŠ‘åˆ¶å¾®ç’°å¢ƒã€‚",
     "regimen": "Dostarlimab 1000mg Q6W + Bevacizumab 15mg/kg Q3Wã€‚"},

    {"cancer": "Ovarian", "name": "ğŸ“ DS8201-772 (Enhertu)", "pharma": "AstraZeneca", "drug": "T-DXd", "pos": "P-MT", "sub_pos": ["BRCA / HRD path"], "type": "Ongoing",
     "rationale": "æ¨™é¶ HER2 ADC ç”¨æ–¼ç¶­æŒéšæ®µï¼Œæ¸…é™¤ HER2 è¡¨ç¾ä¹‹å¾®å°æ®˜ç•™ç—…ç¶ã€‚",
     "regimen": "T-DXd 5.4mg/kg IV Q3Wã€‚"},
]

# --- 3. AI æ¨¡å‹å·¡é‚åŠŸèƒ½ ---
def get_gemini_model():
    try:
        available_models = [m.name for m in genai.list_models() if 'generateContent' in m.supported_generation_methods]
        target_model = next((m for m in available_models if 'gemini-1.5-flash' in m), None)
        if not target_model: target_model = next((m for m in available_models if 'gemini-pro' in m), None)
        if target_model: return genai.GenerativeModel(target_model)
    except: return None

# --- 4. å´é‚Šæ¬„ï¼šæ‚£è€…åˆ†æåŠ©ç† ---
with st.sidebar:
    st.markdown("<h3 style='color: #6A1B9A;'>ğŸ¤– AI å¯¦è­‰åª’åˆåŠ©ç†</h3>", unsafe_allow_html=True)
    api_key = st.text_input("Gemini API Key", type="password")
    with st.expander("âœ¨ æ‚£è€…ç—…æ­·æ•¸æ“šåˆ†æ", expanded=True):
        p_notes = st.text_area("è¼¸å…¥æ‘˜è¦ (å«åˆ†æœŸ/ç´°èƒ/æ¨™è¨˜)", placeholder="ä¾‹å¦‚ï¼šEC IIIæœŸ, p53 mutation, HER2 2+...", height=220)
        if st.button("ğŸš€ é–‹å§‹åˆ†æ"):
            if api_key and p_notes:
                try:
                    genai.configure(api_key=api_key)
                    model = get_gemini_model()
                    prompt = f"åˆ†æç—…æ­·ï¼š{p_notes}ã€‚è«‹åƒè€ƒå¯¦è­‰åº«ï¼š{all_trials_db}ã€‚å»ºè­°é©åˆè·¯å¾‘èˆ‡ç†ç”±ã€‚"
                    st.write(model.generate_content(prompt).text)
                except Exception as e: st.error(f"AI ç•°å¸¸: {e}")

# --- 5. ä¸»é é¢ï¼šå°èˆªåœ°åœ– ---
st.markdown("<div class='main-title'>å©¦ç™Œè‡¨åºŠå°èˆªå„€è¡¨æ¿ (2026 æ——è‰¦æ¥µé‡æ•´åˆç‰ˆ)</div>", unsafe_allow_html=True)
cancer_type = st.radio("ç¬¬ä¸€æ­¥ï¼šé¸æ“‡ç™Œç—‡é¡å‹", ["Endometrial", "Ovarian", "Cervical"], horizontal=True)

cols = st.columns(len(guidelines_nested[cancer_type]))
stages_data = guidelines_nested[cancer_type]

for i, stage in enumerate(stages_data):
    with cols[i]:
        st.markdown(f"""<div class='big-stage-card card-{stage['css']}'><div class='big-stage-header header-{stage['css']}'>{stage['header']}</div>""", unsafe_allow_html=True)
        for sub in stage['subs']:
            st.markdown(f"""<div class='sub-block'><div class='sub-block-title'>ğŸ“˜ {sub['title']}</div><div class='sub-block-content'>{sub['content']}</div>""", unsafe_allow_html=True)
            rel_trials = [t for t in (all_trials_db) if t["cancer"] == cancer_type and t["pos"] == stage["id"] and any(s in sub["title"] for s in t["sub_pos"])]
            for t in rel_trials:
                label = f"{t.get('pharma', 'N/A')} | {t['name']} | {t['drug']}"
                with st.popover(label, use_container_width=True):
                    st.success(f"**æ ¸å¿ƒçµè«–æ‘˜è¦:** {t.get('pop_results', t.get('results_short', 'æ‹›å‹Ÿä¸­'))}")
                    unique_key = f"sync_{t['name']}_{cancer_type}_{stage['id']}_{sub['title'].replace(' ', '')}"
                    if st.button("ğŸ“Š åŒæ­¥çœ‹æ¿ç´°ç¯€", key=unique_key):
                        st.session_state.selected_trial = t['name']
                        st.rerun() # å¼·åˆ¶åŒæ­¥åˆ·æ–°
            st.markdown("</div>", unsafe_allow_html=True)
        st.markdown("</div>", unsafe_allow_html=True)

# --- 6. æ·±åº¦æ•¸æ“šçœ‹æ¿ (æ¥µé‡åŒ–è³‡è¨Šå±•ç¤ºå€) ---
st.divider()
st.subheader("ğŸ“‹ è‡¨åºŠç ”ç©¶æ¥µé‡åŒ–æ•¸æ“šåº« (Published Milestones & Ongoing Trials)")
all_list = all_trials_db # åˆä½µæ¸…å–®

# æ ¹æ“šç›®å‰é¸æ“‡çš„ç™Œç—‡éæ¿¾é¸é …
filtered_names = [t["name"] for t in all_list if t["cancer"] == cancer_type]

if not filtered_names:
    st.info("è©²ç™Œç—‡é¡åˆ¥ä¸‹ç„¡é©ç”¨é …ç›®ã€‚")
else:
    try: curr_idx = filtered_names.index(st.session_state.selected_trial)
    except: curr_idx = 0

    selected_name = st.selectbox("ğŸ¯ å¿«é€Ÿé¸æ“‡ç ”ç©¶è¨ˆç•«ä»¥æŸ¥é–±è©³ç´°å…§å®¹ï¼š", filtered_names, index=curr_idx, key="trial_selector")
    st.session_state.selected_trial = selected_name
    t = next(it for it in all_list if it["name"] == selected_name)

    st.markdown(f"<div class='detail-section'>", unsafe_allow_html=True)
    st.markdown(f"<h2 style='color:#004D40; border-bottom:3px solid #E0E0E0; padding-bottom:10px; font-weight:900;'>ğŸ“‹ {t['name']} æ·±åº¦åˆ†æå ±å‘Š</h2>", unsafe_allow_html=True)

    r1, r2 = st.columns([1.3, 1])
    with r1:
        st.markdown("<div style='background:#E3F2FD; border-left:10px solid #1976D2; padding:15px; border-radius:10px;'><b>ğŸ’‰ Rationale & Regimen (æ©Ÿè½‰èˆ‡åˆ†çµ„çµ¦è—¥)</b></div>", unsafe_allow_html=True)
        st.write(f"**è—¥å» :** {t.get('pharma', 'N/A')}")
        st.write(f"**æ ¸å¿ƒé…æ–¹:** {t['drug']}")
        
        # æ¥µé‡åŒ–çµ¦è—¥æ–¹æ¡ˆå±•ç¤º
        st.markdown("<div class='regimen-box'><b>è©³ç´°çµ¦è—¥æ–¹æ¡ˆ (Dosing Protocol):</b><br>" + t.get('regimen', 'è©³è¦‹ Protocol å…·é«”åŠ‘é‡èªªæ˜ã€‚') + "</div>", unsafe_allow_html=True)
        
        st.success(f"**ç§‘å­¸ç†æ“š (Scientific Rationale):** {t.get('rationale', 'æ—¨åœ¨æŒ‘æˆ°ç¾æœ‰ SoC ç“¶é ¸ï¼Œæå‡å­˜æ´»ç²ç›Šã€‚')}")
        

    with r2:
        st.markdown("<div style='background:#FFF8E1; border-left:8px solid #FBC02D; padding:15px; border-radius:10px;'><b>ğŸ“ˆ Key Outcomes (æœ€æ–°ç”Ÿå­˜èˆ‡ç·©è§£æ•¸æ“š)</b></div>", unsafe_allow_html=True)
        st.markdown(f"""
            <div style='text-align:center; background:white; padding:15px; border:2px solid #FFE082; border-radius:12px;'>
                <div style='font-size: 14px; color: #795548; font-weight:700; margin-bottom:5px;'>Survival Metrics (PFS/OS/HR/ORR)</div>
                <div class='hr-big-val'>{t.get('outcomes', t.get('results', 'Ongoing Recruitment'))}</div>
            </div>
        """, unsafe_allow_html=True)
        

    st.divider()
    r3, r4 = st.columns(2)
    with r3:
        st.markdown("<div style='background:#E8F5E9; border-left:8px solid #2E7D32; padding:15px; border-radius:10px;'><b>âœ… Inclusion Criteria (é—œéµç´å…¥æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for inc in t.get('inclusion', ['ç¬¦åˆç‰¹å®šåˆ†å­æ¨™è¨˜èˆ‡åˆ†æœŸè¦å®šã€‚']): st.write(f"â€¢ **{inc}**")
    with r4:
        st.markdown("<div style='background:#FFEBEE; border-left:8px solid #C62828; padding:15px; border-radius:10px;'><b>âŒ Exclusion Criteria (é—œéµæ’é™¤æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for exc in t.get('exclusion', ['æ’é™¤æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…æˆ–è‚ºéƒ¨çº–ç¶­åŒ–å²ã€‚']): st.write(f"â€¢ **{exc}**")
    st.markdown("</div>", unsafe_allow_html=True)
